<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23743769</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>08</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1615-6692</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Herz</Title>
          <ISOAbbreviation>Herz</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.</ArticleTitle>
        <Pagination>
          <StartPage>868</StartPage>
          <EndPage>880</EndPage>
          <MedlinePgn>868-80</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00059-013-3816-0</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Therapy with ergot-derivative dopamine agonists (ergot-DAs) is suspected to cause or promote the development of insufficiency and regurgitation in previously normal cardiac valves. Thus, we conducted a systematic review and meta-analysis of the literature to determine whether administration of cabergoline, i.e., an ergot-DA used to treat Parkinson's disease (PD) or hyperprolactinemia, is associated with an increased risk of valve regurgitation compared with pharmacological regimens not comprising ergot-DAs or with no therapy.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Observational studies were selected from the Pubmed and Embase databases. Studies had to have assessed the prevalence, odds, or risk of cardiac valve regurgitation in patients who underwent chronic treatment with cabergoline for PD or hyperprolactinemia compared with patients with the same diseases whose therapy did not include cabergoline or another ergot-DA. Separate meta-analyses were performed for PD and hyperprolactinemia patients.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">On the basis of five studies, 634 PD patients were taking cabergoline, while 9,120 PD patients were treated with dopa/dopamine decarboxylase inhibitor, alone or associated with a non-ergot DA. Valvular regurgitation of any degree - at one cardiac valve or more - was more frequent in PD patients who were taking cabergoline compared to those treated with a non-ergot DA agent or not treated with any dopamine agonist [adjusted (inverse variance: iv) odds ratio: 7.25 95 % CI: 3.71-14.18; p &lt; 0.0001]. On the other hand, pooled data from seven studies showed that patients with hyperprolactinemia who were taking cabergoline (n = 444) exhibited significantly higher odds of mild- to-moderate tricuspid regurgitation compared to untreated controls (n = 954) [adjusted (iv) odds ratio: 1.92 95 % CI:1.34-2.73; p = 0.0003]. No significant differences in mitral or aortic valve regurgitation were detected between hyperprolactinemic patients taking cabergoline and controls.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In PD patients, the risk of valvular regurgitation of any grade involving one or more cardiac valves was proven to be strongly associated with cabergoline treatment. Furthermore, based on our results, hyperprolactinemic patients taking cabergoline have an increased risk of mild-to-moderate tricuspid valve regurgitation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>De Vecchis</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiology Unit , Presidio Sanitario Intermedio"Elena d'Aosta", Via Cagnazzi 29, 80137, Naples, Italy, r.de.vecchis@alice.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Esposito</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ariano</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>06</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Herz</MedlineTA>
        <NlmUniqueID>7801231</NlmUniqueID>
        <ISSNLinking>0340-9937</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004873" MajorTopicYN="N">Ergolines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006349" MajorTopicYN="N">Heart Valve Diseases</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23743769</ArticleId>
        <ArticleId IdType="doi">10.1007/s00059-013-3816-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>J Am Soc Echocardiogr. 2003 Jul;16(7):777-802</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12835667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2007 Jan 4;356(1):29-38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17202453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2007 Jan 4;356(1):6-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17202450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2007 Jan 4;356(1):39-46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17202454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2011 Sep;14(3):259-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21221817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acta Cardiol. 2012 Apr;67(2):245-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22641985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Saf. 2012 Feb 1;35(2):159-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22204718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2009;12(3):153-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18594989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2008 Oct;93(10):3777-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18682513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Neurol Neurosurg. 2007 May;109(4):350-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17307289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Endocrinol (Oxf). 2009 Jan;70(1):104-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19128367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int Rev Psychiatry. 2007 Oct;19(5):523-30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17896232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Cardiol Rep. 2012 Apr;14(2):190-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22350692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Heart Valve Dis. 2010 Nov;19(6):797-800</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21214109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Endocrinol Invest. 2008 Dec;31(12):1119-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19246980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postgrad Med J. 2010 Nov;86(1021):648-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20956397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BMJ. 2009 Jul 21;339:b2700</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19622552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mov Disord. 2011 Apr;26(5):801-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21671508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Endocrinol. 2008 Oct;159(4):R11-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18625690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mov Disord. 2006 Aug;21(8):1261-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16685692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heart. 2004 Oct;90(10):1224-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15367531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mov Disord. 2006 Aug;21(8):1109-13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16622856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pituitary. 2012 Mar;15(1):44-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21847572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mov Disord. 2008 May 15;23(7):935-941</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18398916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurology. 2006 Oct 10;67(7):1225-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17030757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs Aging. 2003;20(11):847-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12964891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Indian J Endocrinol Metab. 2011 Apr;15(2):137-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21731877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2004 Apr 10;363(9416):1179-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15081648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Clin Pract. 2008 Dec;62(12):1864-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18462372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Endocrinol. 2008 Oct;159(4):363-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18703568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2003 Mar 13;348(11):1005-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12637610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mov Disord. 2007 Oct 15;22(13):1936-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17659636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo Clin Proc. 2002 Feb;77(2):139-47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11838647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Endocrinol. 2008 Jul;159(1):1-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18456868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch Neurol. 2007 Dec;64(12):1721-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18071034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Internist (Berl). 2004 Oct;45(10):1136-46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15365640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2008 Sep;93(9):3348-56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18559921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mov Disord. 2007 Jan 15;22(2):234-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17094087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Psychiatry. 2007 Aug;12(8):707-47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17549063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Pharmacol. 2005 Apr 25;513(3):225-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15862804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2000 Sep;85(9):3053-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10999785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Intern Med. 2008 Jan;263(1):90-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18036161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Ther. 2006 Aug;28(8):1065-1078</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16982285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2010 Mar;95(3):1025-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20130078</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
